Two lecturers at Al-Qadisiyah University, Professor Dr. Miqdad Erhim Kazem from the College of Science and Dr. Salam Hussein Alwan from the College of Dentistry, obtained a new patent entitled (An innovative compound derived from diaryl beta-lactam (3-CDBA) that provides the possibility of inhibiting the growth of cancer cells ( TCP-1026, HL-60)

The aim of the patent is to provide comprehensive information on how to prepare a beta-lactam compound (3-CDBA), which was used for a toxicity test on human cells infected with leukemia (HL-60), pancreatic cancer (TCP-1026), and healthy ones (WRL68). For comparison’s sake. According to the results obtained, the half inhibitory concentration (IC50) reached 91.55 µg/ml (HL-60) through the reaction of the beta-lactam derivative with the leukemia cell line (TCP-1026). As for the pancreatic cancer cell line (TCP-1026), the inhibitory concentration reached The half-inhibitory concentration equals 141.3 µg\ml, while the half-inhibitory concentration for healthy cells reached 353.8 µg\ml WRL68, which is a good result, meaning that the beta-lactam derivative kills cancer cells and has a very little effect on healthy cells because they need a higher concentration to kill half of the healthy cells. This is also a good result that enhances the possibility of using the aforementioned compound in inhibiting the growth of cancer cells. This prepared compound can be used in (the Ministry of Health, the Ministry of Industry, pharmaceutical manufacturing companies, cancer research centers and research centers in Iraqi universities).

———————————–

Website:
https://qu.edu.iq/
Facebook:
https://facebook.com/qadisiyah2
https://facebook.com/qadisiyah3
Twitter:
https://twitter.com/qu_univ87
Instagram:
https://www.instagram.com/qdis.2
Telegram:
https://t.me/queduiq
youtube:
https://youtube.com/@user-lx8qe6ck3h